Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS

PHASE4UnknownINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Hidradenitis Suppurativa
Interventions
PROCEDURE

Wide Excision

Wide excision is performed under general anaesthesia or procedural sedation and analgesia (PSA). All lesional tissue, including fibrosis, is electrosurgically removed until the area is clear. The subcutaneous fat and epithelised sinus floors are left intact where possible. The wounds are left open to heal by secondary intention.

DRUG

Adalimumab Injection

Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2 until end of study or last surgery.

Trial Locations (1)

Unknown

RECRUITING

Erasmus MC, Rotterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Prothya Biosolutions

INDUSTRY

lead

Erasmus Medical Center

OTHER

NCT03221621 - Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS | Biotech Hunter | Biotech Hunter